Episode Details

Back to Episodes

Exploring the role of BTK inhibitors in mantle cell lymphoma: sequencing & managing adverse events

Episode 266 Published 1 year, 11 months ago
Description

Today's podcast focuses on the role of BTK inhibitors (BTKis) in the treatment of mantle cell lymphoma (MCL). You will hear from experts Krish Patel, MD, Providence Swedish Cancer Institute, Seattle, WA, Marek Trněný, MD, PhD, Charles University Hospital, Prague, Czech Republic, Michael Wang, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, and Craig Portell, MD, University of Virginia, Charlottesville, VA. They share updates on trials investigating BTKis in the frontline treatment of MCL, including the ECHO (NCT02972840), SHINE (NCT01776840), and TRIANGLE (NCT02858258) studies. They then go on to discuss how these agents are optimally sequenced and give advice for managing cardiac toxicities associated with BTKis.

Listen Now

Love PodBriefly?

If you like Podbriefly.com, please consider donating to support the ongoing development.

Support Us